Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Di...

New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose grou...

Related Keywords

United States ,Japan ,Calgary ,Alberta ,Canada ,California ,San Diego ,Spring House ,British Columbia ,Horsham ,Saskatchewan ,Americans ,Canadian ,Taylor Francis ,Remo Panaccione ,Bridget Kimmel ,Jan Wehkamp ,Crohn Colitis Foundation ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,National Cancer Institute Surveillance ,End Results Program ,Japan Pharmaceuticals ,None Of The Janssen Pharmaceutical Companies ,National Institutes Of Health Surveillance ,Drug Administration ,Exchange Commission ,Companies Of Johnson ,University Of Calgary ,European Medicines Agency ,Canadian Agency For Drugs Technologies In Health ,Devices Agency ,Johnson ,Digestive Disease ,Inflammatory Bowel Disease Unit ,Janssen Global Trial Finder ,National Institutes ,Health Surveillance ,End Results ,Vice President ,Gastroenterology Disease Area Leader ,Janssen Research ,Simple Endoscopic Score ,Disease Activity Index ,Ulcerative Colitis ,Prescribing Information ,Medication Guidefor ,Reversible Encephalopathy Syndrome ,Medication Guide ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Guselkumab Maintenance Therapy ,Severely Active Crohn ,Biologic Failure ,Pooled Safety Analysis Through ,Cumulative Safety ,Patients Treated ,Long Term Pooled Safety Analysis ,Accessed May ,Achieved Clinical Remission ,Corticosteroid Free Remission Through ,Cancer Institute Surveillance ,Statistics Review ,Incidence Ratio ,Participants With Moderately ,Monoclonal Antibody Specific ,Study Conducted ,Active Psoriatic ,Canadian Agency ,Medical Devices ,Tremfya Report ,